Baicalin Exerts a Protective Effect in Diabetic Nephropathy by Repressing Inflammation and Oxidative Stress Through the SphK1/S1P/NF-κB Signaling Pathway

References

• Selby NM, Taal MW. An updated overview of diabetic nephropathy: diagnosis, prognosis, treatment goals and latest guidelines. Diabetes Obes Metab. 2020;22(S1):3–15. doi:10.1111/dom.14007
   PubMedGoogle Scholar
• Samsu N. Diabetic nephropathy: challenges in pathogenesis, diagnosis, and treatment. Biomed Res Int. 2021;2021:1497449. doi:10.1155/2021/1497449
   PubMed Web of Science ®Google Scholar
• Moreno JA, Gomez-Guerrero C, Mas S, et al. Targeting inflammation in diabetic nephropathy: a tale of hope. Expert Opin Investig Drugs. 2018;27(11):917–930. doi:10.1080/13543784.2018.1538352
   PubMed Web of Science ®Google Scholar
• Hernandez LF, Eguchi N, Whaley D, Alexander M, Tantisattamo E, Anti-Oxidative IH. Therapy in diabetic nephropathy. Front Biosci. 2022;14(2):14. doi:10.31083/j.fbs1402014
   Google Scholar
• Zoja C, Xinaris C, Macconi D. Diabetic nephropathy: novel molecular mechanisms and therapeutic targets. Front Pharmacol. 2020;11:586892. doi:10.3389/fphar.2020.586892
   PubMed Web of Science ®Google Scholar
• Palabıyık E, Sulumer AN, Uguz H, et al. Assessment of hypolipidemic and anti-inflammatory properties of walnut (Juglans regia) seed coat extract and modulates some metabolic enzymes activity in triton WR-1339-induced hyperlipidemia in rat kidney, liver, and heart. J Mol Recognit. 2023;36(3):e3004. doi:10.1002/jmr.3004
   PubMed Web of Science ®Google Scholar
• Huang T, Liu Y, Zhang C. Pharmacokinetics and bioavailability enhancement of baicalin: a review. Eur J Drug Metab Pharmacokinet. 2019;44(2):159–168. doi:10.1007/s13318-018-0509-3
   PubMed Web of Science ®Google Scholar
• Singh S, Meena A, Luqman S. Baicalin mediated regulation of key signaling pathways in cancer. Pharmacol Res. 2021;164:105387. doi:10.1016/j.phrs.2020.105387
   PubMed Web of Science ®Google Scholar
• Xu M, Li X, Song L. Baicalin regulates macrophages polarization and alleviates myocardial ischaemia/reperfusion injury via inhibiting JAK/STAT pathway. Pharm Biol. 2020;58(1):655–663. doi:10.1080/13880209.2020.1779318
   PubMed Web of Science ®Google Scholar
• Ganguly R, Kumar R, Pandey AK. Baicalin provides protection against fluoxetine-induced hepatotoxicity by modulation of oxidative stress and inflammation. World J Hepatol. 2022;14(4):729–743. doi:10.4254/wjh.v14.i4.729
   PubMed Web of Science ®Google Scholar
• Ou Y, Zhang W, Chen S, Deng H. Baicalin improves podocyte injury in rats with diabetic nephropathy by inhibiting PI3K/Akt/mTOR signaling pathway. Open Med. 2021;16(1):1286–1298. doi:10.1515/med-2021-0335
   Web of Science ®Google Scholar
• Zhang S, Xu L, Liang R, Yang C, Wang P. Baicalin suppresses renal fibrosis through microRNA-124/TLR4/NF-κB axis in streptozotocin-induced diabetic nephropathy mice and high glucose-treated human proximal tubule epithelial cells. J Physiol Biochem. 2020;76(3):407–416. doi:10.1007/s13105-020-00747-z
   PubMed Web of Science ®Google Scholar
• Yang M, Kan L, Wu L, Zhu Y, Wang Q. Effect of baicalin on renal function in patients with diabetic nephropathy and its therapeutic mechanism. Exp Ther Med. 2019;17(3):2071–2076. doi:10.3892/etm.2019.7181
   PubMed Web of Science ®Google Scholar
• Ma L, Wu F, Shao Q, Chen G, Xu L, Lu F. Baicalin alleviates oxidative stress and inflammation in diabetic nephropathy via Nrf2 and MAPK signaling pathway. Drug Des Devel Ther. 2021;15:3207–3221. doi:10.2147/DDDT.S319260
   PubMed Web of Science ®Google Scholar
• Pulkoski-Gross MJ, Obeid LM. Molecular mechanisms of regulation of sphingosine kinase 1. Biochim Biophys Acta Mol Cell Biol Lipids. 2018;1863(11):1413–1422. doi:10.1016/j.bbalip.2018.08.015
   PubMed Web of Science ®Google Scholar
• Orr Gandy KA, Obeid LM. Targeting the sphingosine kinase/sphingosine 1-phosphate pathway in disease: review of sphingosine kinase inhibitors. Biochim Biophys Acta Mol Cell Biol Lipids. 2013;1831(1):157–166. doi:10.1016/j.bbalip.2012.07.002
   Web of Science ®Google Scholar
• Deng Y, Lan T, Huang J, Huang H. Sphingosine Kinase-1/sphingosine 1-phosphate pathway in diabetic nephropathy. Chin Med J. 2014;127(16):3004–3010.
   PubMed Web of Science ®Google Scholar
• Chen C, Huang K, Hao J, et al. Polydatin attenuates AGEs-induced upregulation of fibronectin and ICAM-1 in rat glomerular mesangial cells and db/db diabetic mice kidneys by inhibiting the activation of the SphK1-S1P signaling pathway. Mol Cell Endocrinol. 2016;427:45–56. doi:10.1016/j.mce.2016.03.003
   PubMed Web of Science ®Google Scholar
• Gong W, Li J, Chen W, Feng F, Deng Y. Resveratrol inhibits lipopolysaccharide-induced extracellular matrix accumulation and inflammation in rat glomerular mesangial cells by SphK1/S1P2/NF-κB pathway. Diabetes Metab Syndr Obes. 2020;13:4495–4505. doi:10.2147/DMSO.S278267
   PubMed Web of Science ®Google Scholar
• Tanaka T, Iino M. Nuclear translocation of p65 is controlled by Sec6 via the degradation of IκBα. J Cell Physiol. 2016;231(3):719–730. doi:10.1002/jcp.25122
   PubMed Web of Science ®Google Scholar
• John S. Complication in diabetic nephropathy. Diabetes Metab Syndr. 2016;10(4):247–249. doi:10.1016/j.dsx.2016.06.005
   PubMedGoogle Scholar
• Demir Y, Köksal Z. Some sulfonamides as aldose reductase inhibitors: therapeutic approach in diabetes. Arch Physiol Biochem. 2022;128(4):979–984. doi:10.1080/13813455.2020.1742166
   PubMed Web of Science ®Google Scholar
• Turkmen K. Inflammation, oxidative stress, apoptosis, and autophagy in diabetes mellitus and diabetic kidney disease: the four horsemen of the apocalypse. Int Urol Nephrol. 2017;49(5):837–844. doi:10.1007/s11255-016-1488-4
   PubMed Web of Science ®Google Scholar
• Winiarska A, Knysak M, Nabrdalik K, Gumprecht J, Stompór T. Inflammation and oxidative stress in diabetic kidney disease: the targets for SGLT2 Inhibitors and GLP-1 receptor agonists. Int J Mol Sci. 2021;22(19):10822. doi:10.3390/ijms221910822
   PubMed Web of Science ®Google Scholar
• Sever B, Altıntop MD, Demir Y, et al. Identification of a new class of potent aldose reductase inhibitors: design, microwave-assisted synthesis, in vitro and in silico evaluation of 2-pyrazolines. Chem Biol Interact. 2021;345:109576. doi:10.1016/j.cbi.2021.109576
   PubMed Web of Science ®Google Scholar
• Hu Q, Qu C, Xiao X, et al. Flavonoids on diabetic nephropathy: advances and therapeutic opportunities. Chin Med. 2021;16(1):74. doi:10.1186/s13020-021-00485-4
   PubMed Web of Science ®Google Scholar
• Su W, Cao R, He YC, Guan YF, Ruan XZ. Crosstalk of hyperglycemia and dyslipidemia in diabetic kidney disease. Kidney Dis. 2017;3(4):171–180. doi:10.1159/000479874
   Google Scholar
• Vincent AM, Hinder LM, Pop-Busui R, Feldman EL. Hyperlipidemia: a new therapeutic target for diabetic neuropathy. J Peripher Nerv Syst. 2009;14(4):257–267. doi:10.1111/j.1529-8027.2009.00237.x
   PubMed Web of Science ®Google Scholar
• Demir Y, Özaslan MS, Duran HE, Küfrevioğlu Öİ, Beydemir Ş. Inhibition effects of quinones on aldose reductase: antidiabetic properties. Environ Toxicol Pharmacol. 2019;70:103195. doi:10.1016/j.etap.2019.103195
   PubMed Web of Science ®Google Scholar
• Yasuda I, Hasegawa K, Sakamaki Y, et al. Pre-emptive short-term nicotinamide mononucleotide treatment in a mouse model of diabetic nephropathy. J Am Soc Nephrol. 2021;32(6):1355–1370. doi:10.1681/ASN.2020081188
   PubMed Web of Science ®Google Scholar
• Zheng W, Qian C, Xu F, et al. Fuxin Granules ameliorate diabetic nephropathy in db/db mice through TGF-β1/Smad and VEGF/VEGFR2 signaling pathways. Bio Pharmac. 2021;141:111806. doi:10.1016/j.biopha.2021.111806
   Google Scholar
• Lee SY, Choi ME. Urinary biomarkers for early diabetic nephropathy: beyond albuminuria. Pediatr Nephrol. 2015;30(7):1063–1075. doi:10.1007/s00467-014-2888-2
   PubMed Web of Science ®Google Scholar
• Shen Y, Wang S, Liu Y, et al. The effects of salvianolate combined with western medicine on diabetic nephropathy: a systematic review and meta-analysis. Front Pharmacol. 2020;11:851. doi:10.3389/fphar.2020.00851
   PubMed Web of Science ®Google Scholar
• Charlton A, Garzarella J, Jandeleit-Dahm KAM, Jha JC. Oxidative stress and inflammation in renal and cardiovascular complications of diabetes. Biology. 2021;10(1):18. doi:10.3390/biology10010018
   Google Scholar
• Donate-Correa J, Martín-Núñez E, Muros-de-Fuentes M, Mora-Fernández C, Navarro-González JF. Inflammatory cytokines in diabetic nephropathy. J Diabetes Res. 2015;2015:948417. doi:10.1155/2015/948417
   PubMed Web of Science ®Google Scholar
• Mima A. Inflammation and oxidative stress in diabetic nephropathy: new insights on its inhibition as new therapeutic targets. J Diabetes Res. 2013;2013:248563. doi:10.1155/2013/248563
   PubMed Web of Science ®Google Scholar
• Nam JE, Jo SY, Ahn CW, Kim YS. Baicalin attenuates fibrogenic process in human renal proximal tubular cells (HK-2) exposed to diabetic milieu. Life Sci. 2020;254:117742. doi:10.1016/j.lfs.2020.117742
   PubMed Web of Science ®Google Scholar
• Wang C, Xu T, Lachance BB, et al. Critical roles of sphingosine kinase 1 in the regulation of neuroinflammation and neuronal injury after spinal cord injury. J Neuroinflammation. 2021;18(1):50. doi:10.1186/s12974-021-02092-4
   PubMed Web of Science ®Google Scholar
• Crespo I, San-Miguel B, Sánchez DI, et al. Melatonin inhibits the sphingosine kinase 1/sphingosine-1-phosphate signaling pathway in rabbits with fulminant hepatitis of viral origin. J Pineal Res. 2016;61(2):168–176. doi:10.1111/jpi.12335
   PubMed Web of Science ®Google Scholar
• Abdel Baky NA, Al-Najjar AH, Elariny HA, Sallam AS, Mohammed AA. Pramipexole and Lactoferrin ameliorate Cyclophosphamide-Induced haemorrhagic cystitis via targeting Sphk1/S1P/MAPK, TLR-4/NF-κB, and NLRP3/caspase-1/IL-1β signalling pathways and modulating the Nrf2/HO-1 pathway. Int Immunopharmacol. 2022;112:109282. doi:10.1016/j.intimp.2022.109282
   PubMed Web of Science ®Google Scholar
• Youssef NS, Elzaitony AS, Abdel Baky NA. Diacerein attenuate LPS-induced acute lung injury via inhibiting ER stress and apoptosis: impact on the crosstalk between SphK1/S1P, TLR4/NFκB/STAT3, and NLRP3/IL-1β signaling pathways. Life Sci. 2022;308:120915. doi:10.1016/j.lfs.2022.120915
   PubMed Web of Science ®Google Scholar